F-star Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

F-star Therapeutics (NASDAQ: FSTX) announced its participation in the upcoming Ladenburg Thalmann Healthcare Conference and William Blair Biotech Focus Conference. The events will be held virtually on July 13 and July 14, 2021, respectively. F-star's CEO, Eliot Forster, will engage in a fireside chat at the Ladenburg conference, while CSO, Neil Brewis, will participate in a panel discussion at the William Blair conference. These conferences aim to enhance F-star's visibility within the biopharmaceutical sector.

Company Leadership will Speak at Ladenburg Thalmann 2021 Healthcare Conference and the William Blair 2021 Biotech Focus Conference

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that the company will participate in two virtual investor conference events next week.

Details are as follows:

Ladenburg Thalmann Healthcare Conference 2021

Fireside chat with F-star CEO, Eliot Forster
Date: Tuesday, July 13, 2021
Time: 9:30 a.m. to 10:00 a.m. ET
Management will be available for 1:1 meetings Tuesday, July 13th

William Blair Biotech Focus Conference 2021

Neil Brewis, CSO, will speak on a panel discussing “Moving Beyond Monoclonals: The Potential of Multispecific Therapies.”
Date: Wednesday, July 14, 2021
Time: 11:20 a.m. to 12:20 p.m. ET
Management will be available for 1:1 meetings Wednesday, July 14th

About F-star Therapeutics, Inc.

F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb²™) format, F-star’s mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability. For more information visit www.f-star.com and follow us on LinkedIn and Twitter.

For further information, please contact:

For investor inquiries
Lindsey Trickett
VP Investor Relations & Communications
+1 240 543 7970
lindsey.trickett@f-star.com

For media inquiries
Helen Shik
Shik Communications LLC
+1 617 510 4373
Shik.Helen10@gmail.com

FAQ

When will F-star Therapeutics participate in the Ladenburg Thalmann Healthcare Conference?

F-star Therapeutics will participate in the Ladenburg Thalmann Healthcare Conference on July 13, 2021.

Who is speaking for F-star Therapeutics at the William Blair Biotech Focus Conference?

Neil Brewis, the CSO of F-star Therapeutics, will speak at the William Blair Biotech Focus Conference.

What is the focus of the panel discussion involving F-star at the William Blair Conference?

The panel discussion will focus on 'Moving Beyond Monoclonals: The Potential of Multispecific Therapies.'

What time will F-star's CEO speak at the Ladenburg Thalmann Healthcare Conference?

Eliot Forster, CEO of F-star, will speak from 9:30 a.m. to 10:00 a.m. ET.

What are F-star Therapeutics' goals in immunotherapy?

F-star aims to develop next-generation immunotherapies that block tumor immune evasion, offering more durable patient benefits.